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Abstract 
Three dogs were investigated for chronic unilateral nasal discharge. In all cases CT imaging 
showed an intranasal mass causing turbinate lysis and no evidence of metastasis. Cytology in 
cases 1 (a 14-year-old neutered male crossbreed dog) and 2 (a five-year-old neutered male 
German Shepherd dog) demonstrated a pleomorphic cell population with variable intracellular 
pigment suspicious of melanocytic neoplasia. Histopathology with immunohistochemistry 
(Melan-A and vimentin, plus PNL-2 in one case) confirmed the diagnosis of melanoma in all 
dogs. All dogs were treated with megavoltage radiotherapy using linear accelerators. Cases 1 and 
3 (a 9-year-old neutered female beagle dog) received a hypofractionated (4x8 Gy) protocol and 
case 2 received a definitive (12x4 Gy) protocol. Complete remission was demonstrated on repeat 
CT scan 5 months after diagnosis in case 1 and 7 months in case 2. Stable disease was 
documented on CT at four months for case 3, however, clinical signs in this dog remained 
controlled for 10 months in total. Case 1 died of unrelated causes 5 months after diagnosis, case 
2 was euthanased due to the development of seizures 13 months after diagnosis, and case 3 was 
lost to follow-up 12 months after diagnosis. Melanoma should be considered as a rare differential 
diagnosis for primary nasal neoplasia in the dog and radiation therapy can be used as effective 
local therapy. 
 
Keywords: dog; canine; nasal; cancer; melanoma; radiotherapy 
  
D
ow
nl
oa
de
d 
by
 [R
oy
al 
Ve
ter
ina
ry
 C
oll
eg
e] 
at 
08
:16
 18
 O
cto
be
r 2
01
7 
1. Introduction 
Most intranasal neoplasms in the dog are carcinomas and sarcomas (Madewell et al. 1976, 
Kubicek et.al 2016) and rarely other tumours, including lymphoma (Patnaik 1989), mast cell 
tumours (Naganobu et al. 2000), transmissible venereal tumours (Papazoglou et al. 2001), 
haemangiosarcoma (Fujita et al. 2008), neuroblastoma (Ueno et al. 2007) and multilobular 
osteochondrosarcoma (Patnaik 1989) have been reported. The primary treatment of most canine 
intranasal neoplasms is radiotherapy (Lana et al. 2004; Lawrence et al. 2010) often with adjuvant 
chemotherapy (Lana et al. 2004; Adams et al. 2005). Neoadjuvant surgical debulking has also 
been described, but has not been shown to improve clinical outcome (Morris et al. 1994; Adams 
et al. 2005).  
Most intranasal cancers in humans are squamous cell carcinomas (Peryaga et al. 2016). Primary 
intranasal melanoma is uncommon, accounting for approximately 3.6% of all nasal tumours in 
people (Gouldesbrough et al. 1992). Treatment typically involves radical surgery and adjunctive 
radiotherapy (Lin et al. 2003). Intranasal melanoma in the dog is considered exceptionally rare, 
with one case report in the literature describing a dog treated with surgical debulking (via 
rhinotomy) and adjunctive radiotherapy (Hicks & Fidel 2006). 
Canine melanoma typically occurs in the oral cavity, lip, haired skin and digits, with other sites 
constituting 2% of the total (Smith et al. 2002). Melanomas originating from mucous 
membranes, specifically oral, are usually associated with invasive behaviour and a high 
metastatic rate (Millanta et al. 2002). Local control is achieved with radical surgery or 
hypofractionated radiotherapy. However, most dogs will die or be euthanased as a result of 
metastatic disease (Tuohy et al. 2014). 
This report describes three cases of canine intranasal melanoma treated with radiotherapy. 
  
2. Case-series 
2.1. Case 1 
 
Case 1 was a 14-year-old neutered male, 23.5 kg crossbreed dog, presented for evaluation of a 5 
month history of sneezing and muco-haemorrhagic, right-sided nasal discharge. Physical 
examination revealed reduced airflow through the right naris but was otherwise unremarkable. A 
complete blood count, serum biochemistry panel and cytology of both mandibular lymph nodes 
were unremarkable.  
Contrast computed tomography (CT) of the head, neck, thorax and abdomen was performed 
under general anaesthesia. A soft tissue attenuating mass was present in the right nasal cavity 
(measuring approximately 4.8 cm rostrocaudally, 1.7 cm dorsoventrally and 1.9 cm 
lateromedially), associated with significant turbinate lysis and focal destruction of the right 
nasomaxillary suture (Figure 1). No metastatic lesions were identified. Rhinoscopy was used to 
obtain biopsy and cytology samples. 
Cytology of the nasal mass demonstrated a population of pleomorphic polyhedral to spindloid 
cells (Figure 2.1-2.2). Nuclei were centrally placed and round with stippled chromatin and one or 
multiple prominent nucleoli; occasional macronuclei or multinucleate cells were observed. The 
cellular pleomorphism and presence of green pigment in some cells was suggestive of a 
melanoma. Histopathology described pleomorphic, round to polygonal cells containing varying 
numbers of nuclei, abundant eosinophilic cytoplasm with light-brown intracellular granules, and 
fewer than one mitosis in ten high-power (x 400) fields. The histogenesis of the tumour was 
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unclear; melanoma, olfactory neuroblastoma, neuroendocrine tumour and undifferentiated 
carcinoma were considered differential diagnoses. Fontana-Masson stain for melanin granules 
was weakly positive. Immunohistochemical labelling (Table 1) showed the neoplastic cells to 
stain strongly positive for melanocytic antigen recognized by cytotoxic T lymphocytes (Melan-
A), vimentin and anti-melanoma antibody (PNL-2), and negative for S100 protein, smooth 
muscle actin (SMA) and multiple myeloma-1 protein (MUM-1), consistent with the diagnosis of 
melanoma (Ramos-Vara & Miller 2011; Busam & Jungbluth 1999). 
The dog was treated with a hypofractionated radiotherapy protocol using a Varian 6MV “Clinac” 
linear accelerator and CT-based computer-planning was performed with CadPlan 3.0 software 
(version 1.3, Varian-Dosetek, Palo Alto, CA, USA).  The dog received general anaesthesia for 
each fraction (premedicated with 0.2 mg/kg BW butorphanol intravenously, induced with a total 
dose of 2.4 mg/kg BW propofol, given intravenously “to effect”, maintained with isofluorane in 
100% oxygen via endotracheal tube). Positioning was facilitated using a bespoke mouth-gag, and 
a combination of polystyrene blocks and tape. A total dose of 32 Gray (Gy; 1 joule of radiation 
energy absorbed per kilogram of BW) was delivered to the tumour as four, once-weekly 8 Gy 
fractions. A single radiation beam was used; field depth was 98.5 cm, clinical target volume 
(CTV) was 0.6 cm around the gross tumour volume (GTV), and the planning target volume 
(PTV) was 1.0 cm around CTV; eyes and brain were not included in the treatment field.  Lymph 
nodes were not treated. This treatment was tolerated with no apparent adverse effects and 
resulted in rapid and complete resolution of clinical signs. Repeat CT 4 months after treatment 
demonstrated complete response of the nasal tumour (Figure 1) and no evidence of metastatic 
disease. No medical therapy was given. The dog was euthanazed due to discomfort associated 
with a soft tissue sarcoma in its hind leg 5 months after diagnosis; CT scan at this time revealed 
no metastatic disease from either neoplasm, and the diagnosis of soft tissue sarcoma was 
confirmed on immunohistochemistry (negative labelling for Melan-A, positive for vimentin).  
Necropsy was not performed.   
 
2.2.  Case 2 
Case 2 was a five-year-old neutered male, 44 kg German Shepherd dog, presented for a 3 week 
history of intermittent left-sided muco-haemorrhagic, nasal discharge and sneezing. Physical 
examination revealed reduction in left-sided nasal airflow and mild left mandibular 
lymphadenomegaly. Complete blood count, serum biochemistry, urinalysis, activated 
thromboplastin and prothrombin times, and blood pressure were within normal limits. Cytology 
of both mandibular lymph nodes was unremarkable. 
CT scan of the head, thorax and abdomen demonstrated a large, contrast-enhancing soft tissue 
lesion in the left nasal cavity (measuring approximately 6.4 cm rostrocaudally, 2.7 cm 
dorsoventrally and 2.4 cm lateromedially), causing significant turbinate lysis and focal 
destruction of the left nasomaxilliary bones (Figure 3). No evidence of detectable metastasis was 
identified. Cytology and biopsy samples were obtained via rhinoscopy. 
Cytology showed round to spindle-shaped cells with moderate anisocytosis and anisokaryosis, 
and variable nucleolar number and morphology. Dark pigment was occasionally seen within 
these cells and melanoma was deemed the most likely diagnosis. Histopathology (Figure 4.1) 
was consistent with a poorly-differentiated, non-pigmented spindle cell malignancy. Mitotic 
activity was 0-2 per x400 field. Immunohistochemical labelling with vimentin, SMA, desmin, 
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neuron-specific enolase, glial fibrillary acidic protein and melan-A was performed. Neoplastic 
cells labelled with vimentin and melan A, supporting the diagnosis of amelanotic melanoma 
(Figures 4.2-4.3, Table 1). 
The dog was treated with a definitive radiotherapy protocol directed to the primary tumour and 
mandibular lymph nodes. For planning CT and treatment delivery, the patient was placed under 
general anaesthesia, (premedicated with intravenous medetomidine [5ug/kg BW] and 
butorphanol [0.015-0.03 mg/kg BW], or medetomidine [7-10 ug/kg BW] alone for later fractions, 
induced with propofol, maintained with sevoflurane in 100% oxygen via endotracheal tube) and 
positioned in sternal recumbency. Immobilization was achieved using a thermoplastic mask and 
a customized head support, secured to a plastic head-frame with four points of fixation.  
Radiotherapy consisted of 12 fractions of 4 Gy on a Monday, Wednesday, Friday basis (48 Gy 
total), delivered using a Dual Energy Linear Accelerator (Clinac 2100C, Varian, Palo Alto, CA, 
USA) with 0.5 cm multi-leaf collimator (MLC). All treatments were carried out at 6 MV, and were 
3D planned from CT using Pinnacle (version 9), with beam collimation using MLC and beam 
modification using dynamic wedges. Planning was carried out with the intent to include 95% of 
the PTV (GTV plus 1-2 cm normal tissue for CTV, planning treatment volume based on clinical 
target volume plus 5 mm, adjusting final planned treatment volume margins manually to spare 
left eye and reduce dose to brain tissue) in the 95-105% iso-dose, i.e. scheduled dose 
heterogeneity less than 15%. The primary tumour was treated with three coplanar beams (left 
lateral oblique 254o; dorsoventral 356o with dynamic wedge; ventrodorsal oblique 160o with 
dynamic wedge). The submandibular lymph nodes were treated with a separate two field plan 
(left lateral 273o; right lateral 83o). Portal imaging was carried out twice during the treatment 
protocol to verify position: no adjustments were required. The lymph nodes were irradiated as 
per the institutional policy for malignant melanoma. In terms of organs at risk, the maximum 
dose to the frontal lobes was 4740 centiGray (cGy): these were not contoured separately from 
the brain. For the whole brain, the minimum dose was 64 cGy, and mean 871 cGy. The mean 
dose to proximal cord was 93 cGy, minimum 14 cGy, maximum 368 cGy. The mean dose for 
the right eye was 4724 cGy, minimum 3476 cGy , maximum 4878 cGy. The mean dose for the 
left eye was 2076 cGy, minimum 1334 cGy, maximum 4413 cGy.  
Concurrent prednisolone at 0.5 mg/kg BW orally, once daily was administered for anti-
inflammatory effect. During the third week of radiation therapy conjunctivitis in the left eye was 
noted; facial nerve function was normal and initially fluorescein uptake of the left cornea was 
negative. Two weeks later a Schirmer tear test demonstrated low tear production in the left eye 
(10 mm) however fluorescein uptake remained negative; oral prednisolone was reduced, topical 
ketorolac (Allergan Pharmaceuticals Ireland, Westport, County Mayo, Ireland) and lubrication 
were introduced, and a buster collar was placed to stop the dog traumatizing the eye. Two 
weeks following however, a deep ulcer was noted. Enucleation was elected over other 
treatments by the owners due to dog's acute discomfort.   
Clinical signs of nasal discharge completely resolved within 4 weeks of starting radiotherapy.  
Seven months after diagnosis, a repeat CT scan of the head, thorax and abdomen showed 
complete remission of the nasal tumour; mucosal thickening and a small amount of fluid was 
present within the nasal cavity, but no contrast-uptake was seen, consistent with a complete 
response to therapy (Figure 3). No evidence of metastatic disease was seen. At this point, 
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firocoxib (Previcox, Merial, Lyon, France) at 5mg/kg BW orally, once daily, was prescribed to for 
potential anti-cancer effect as a COX-2 inhibitor (Proulx et al. 2003; Martinez et al. 2011).  The 
firocoxib therapy was continued for 5 months and clinically no adverse effects of treatment were 
observed; supportive treatment (for example gastroprotectants) were therefore not considered 
necessary. The dog developed seizure activity 13 months after diagnosis and was euthanized 
after further investigations were declined. Necropsy was not performed, and the aetiology of the 
seizures remains unclear. 
 
2.3.  Case 3 
Case 3 was a 9 year-old neutered female, 17.1 kg beagle dog with a 4-week history of sneezing 
and left-sided haemorrhagic nasal discharge. Physical examination, a complete blood count, and 
serum biochemistry panel were unremarkable. Blind nasal biopsies had been performed by the 
referring veterinary surgeon and histopathology demonstrated a diffuse cellular proliferation of 
pleomorphic neoplastic cells containing moderate amounts of pigment. The cells were arranged 
in haphazard bundles, had a polygonal to spindle-shaped morphology, mild anisocytosis and 
anisokaryosis, and contained a moderate amount of deep eosinophilic cytoplasm with variably 
distinct cellular borders. Nuclei varied between round and oval, and were mostly hyperchromatic 
with stippled chromatin and multiple amphophilic nucleoli. Approximately 1 mitotic figure was 
evident per high power field (400x). Malignant melanoma, plasma cell tumour or epithelioid 
haemangiosarcoma were considered likely diagnoses based on cellular morphology and the 
presence of intracellular pigment. The diagnosis of melanoma was confirmed with strong 
positive immunohistochemical labelling with PNL2, S100 and Melan A (MUM1 negative). 
Contrast CT of the head and thorax was performed for radiotherapy planning and staging of 
disease under general anaesthesia. A relatively small soft tissue attenuating mass was present in 
the rostral half of the left nasal cavity (measuring approximately 2.0 cm rostrocaudally, 1.7 cm 
dorsoventrally and 1.1 cm lateromedially), with mild involvement of the nasal bone dorsally and 
the nasal septum medially (Figure 5). No metastatic lesions were identified locoregionally or in 
lungs on the CT scan. Cytology of local lymph nodes was not assessed.     
The dog was treated with a hypofractionated radiotherapy protocol. Planning, set-up and 
anaesthesia were as described in case 1. A total dose of 32 Gy was prescribed to the tumour as 
four, once-weekly 8 Gy fractions, using three fields, consisting of dorsal, right and left lateral 
beams; field depth was 1.6 cm dorsal, 1.8 cm right lateral and 2.4 cm left lateral, CTV was 0.2 
cm around the GTV, and the planning target volume PTV was 0.4 cm around CTV; eyes and 
brain were not included in the treatment field. Lymph nodes were not treated. This treatment was 
tolerated with minimal adverse effects; sneezing episodes and minor epistaxis remained present 
throughout the treatment protocol. Repeat CT of the head only was performed 18 days after the 
treatment due to reports of persistent epistaxis. The CT revealed stable tumour size but with 
decreased contrast uptake. At this point, the dog started therapy with meloxicam (Metacam oral 
suspension for dogs, Boehringer Ingelheim, Ingelheim am Rhein, Germany) at a dose of 0.1 
mg/kg BW orally, once daily, after which clinical signs (sneezing and epistaxis episodes) 
resolved; the course of meloxicam continued for approximately six weeks. The dog remained 
asymptomatic and repeat CT scan (of the head only) four months after completion of the 
treatment revealed continued stability in tumour size (Figure 5). Clinical signs recurred ten 
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months after completion of hypofractionated radiotherapy treatment. Further investigation and 
treatment were declined.  The dog received no further treatment and was lost to follow-up twelve 
months after radiation therapy.    
 
3. Discussion 
Primary nasal melanoma is described in three dogs. In all cases the variable histological 
appearance of melanoma precluded a definitive histomorphological diagnosis (Choi & Kusewitt 
2003; Smedley et al. 2011; Smith et al. 2002). Immunohistochemistry was necessary to provide 
the final diagnosis in all cases after positive staining with Melan-A, PNL-2 and vimentin.  
Canine intranasal melanoma has been successfully treated with surgery and radiotherapy once 
before (Hicks & Fidel 2006). Radiotherapy is a common primary treatment for intranasal 
neoplasia, producing clinical benefit in over 80% of dogs and a median survival time (MST) of 
over 500 days (Fujiwara et al. 2013). Radiotherapy is also effective in controlling oral 
melanomas, with an overall response rate of 83% (Bateman et al. 1994; Proulx et al. 2003) and a 
MST of 80-758 days, depending on factors such as tumour stage, sub-location in the oral cavity 
and the degree of osteolysis (Proulx et al. 2003; Freeman et al. 2003; Kawabe et al. 2015).  
Given its established efficacy, radiotherapy was performed first-line in the dogs in this report; 
surgery was considered unnecessary since all dogs experienced satisfactory control of disease 
with radiotherapy.  
Fifty-three percent of oral melanomas have evidence of metastasis at diagnosis (Williams & 
Packer 2003). Even if local control of the primary tumour has been effective, most dogs will die 
of distant metastasis (Proulx et al. 2003; Freeman et al. 2003). Case 1 did not have metastasis at 
diagnosis or follow-up; the tumour’s low mitotic index may be pertinent in this regard, since a 
low mitotic index has been shown to correlate with indolent behavior of oral melanomas (Esplin 
2008; Spangler & Kass 2006). The existing report of a canine intranasal melanoma also 
describes a low mitotic index and absence of metastasis (Hicks & Fidel 2006), nevertheless the 
short survival of case 1 makes evaluation of the metastatic propensity of this tumour unreliable.  
The metastatic status of case 2 is unknown since the cause of the dog’s seizures is unclear; 
metastasis, local extension of disease or delayed radiation toxicity are possible aetiologies. It is 
not possible to comment on the metastatic status of case 3 since thorough staging and restaging 
of disease was declined.   
Cases 1 and 3 received hypofractionated radiotherapy, since no significant difference in 
response and survival between definitive and hypofractionated protocols for canine oral 
melanoma have been demonstrated (Proulx et al. 2003). Case 2 received definitive 
radiotherapy, which has been shown to be the most effective protocol for primary canine 
intranasal neoplasia (Théon et al. 1993; Adams et al. 2005), and was also judged to be a safer 
therapy for this dog given the proximity of the tumour to the brain. Definitive protocols are more 
expensive and more likely to cause acute adverse effects than hypofractionated protocols; case 
2 developed a non-healing descemetocele, likely an acute adverse effect of treatment. 
Desmetocoele is an uncommon adverse effect of radiation therapy in dogs, however ulcerative 
keratitis has been reported to occur in 26% dogs where the orbit is included in the radiation field 
(Pinard et al. 2012). Due to the location of this tumour, the dog’s globe received a high dose of 
radiation, and since no pre-existing, or previous ocular disease was reported in this dog, it is 
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considered plausible that ulcerative keratitis was exacerbated by the use of oral prednisolone 
and possibly self-trauma by the patient, resulting in a desmetocoele.  
We are unable to comment on differences in the long-term tumour control between cases 1 and 
2, since case 1 died from unrelated causes five months after treatment and the cause of seizures 
in case 2 remains undetermined. Nevertheless it is interesting that case 3 demonstrated good 
control of clinical signs for ten months before clear signs of disease progression, despite the 
documentation of no more than stable disease on CT follow-up. The low mitotic activity of this 
tumour may signify a relatively indolent behavior in this case. 
Since there is no clear evidence that adjuvant immunotherapy or cytotoxic chemotherapy is 
beneficial in canine melanoma (Proulx et al. 2003; Murphy et al. 2005) none of the dogs in this 
report received medical therapy other than a COX-2 inhibitor (in case 2 and 3). Although the 
effect of COX-2 inhibition has not been investigated in canine melanoma, in certain canine 
cancers COX-2 expression correlates with malignancy and is negatively associated with survival 
(Proulx et al. 2003; Martinez et al. 2011). 
Melanoma should be considered a rare differential diagnosis for primary intranasal neoplasia in 
dogs and immunohistochemistry is useful for definitive diagnosis. These three cases suggest that 
radiotherapy alone can be used to manage this disease.  
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 Legends for figures 
 
 
 
Figure 1. Pre-treatment and post-treatment CT images of Case 1. 1.1: Pre-treatment 
transverse; 1.2: post-treatment transverse; 1.3 pre-treatment longitudinal; 4: post-treatment 
longitudinal. Arrows mark the location of the tumour. 
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Figure 2. Cytology from Case 1: 2.1 shows multinucleate cells (black arrows) with variable 
pigmentation (red arrow). 2.2 shows a high degree of cellular pigment (red arrow) and the 
marked pleomorphism (white arrows). 
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Figure 3. Pre-treatment and post-treatment CT images of Case 2. 3.1: Pre-treatment 
transverse; 3.2: post-treatment transverse; 3.3 pre-treatment longitudinal; 3.4: post-treatment 
longitudinal. Arrows mark the location of the tumour. 
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Figure 4. Histology of the nasal mass in Case 2. 4.1: H&E section (x40) demonstrating poor 
cellular differentiation, which in rare places tended towards spindle cell morphology (black 
arrows). 4.2: positive immunohistochemical labelling for Melan-A (x40). 4.3: positive 
immunohistochemical labelling for vimentin (x40).   
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Figure 5. Pre-treatment and post-treatment CT images of Case 3. 5.1: Pre-treatment 
transverse; 5.2: post-treatment transverse. Arrows mark the tumour. 
 
 
 
  
D
ow
nl
oa
de
d 
by
 [R
oy
al 
Ve
ter
ina
ry
 C
oll
eg
e] 
at 
08
:16
 18
 O
cto
be
r 2
01
7 
Table 1: 
Immunohistochemical 
Marker 
Melanoma Case 1 
(Antibodies used) 
Case 2 
(Antibodies used) 
Vimentin >95% 
tumours 
positive
3,4
 
Positive 
(1º: Clone V9 mouse 
monoclonal anti-; Dako, 
Agilent.  2 º: Dako Flex Kit) 
Positive 
(1º: Clone V9 mouse monoclonal 
anti-; Dako, Agilent.  2 º: Dako 
Flex Kit) 
Cytokeratin Negative
4
 Negative 
(1º: Clone 34βE12 mouse 
monoclonal anti-human; Leica 
Biosystems.  2 º: Leica Bond 
System) 
Not assessed 
Melan-A 59% 
tumours 
positive
2
 
Positive 
(1º: Clone A103, mouse 
monoclonal anti-human; 
Novocastra, Leica Biosystems.  
2 º: Leica Bond System) 
Positive 
(1º: Clone A103 mouse monoclonal 
anti-human; Dako, Agilent.  2 º: 
Dako Flex Kit) 
PNL-2 62% 
tumours 
positive
2
 
Positive 
(1º: Clone HMB45 mouse 
monoclonal; Santa Cruz 
Biotechnology.  2 º: mouse IgG 
kappa binding protein, 
conjugated to horseradish 
peroxidase, Santa Cruz) 
Not assessed 
S-100 76% 
tumours 
positive
1,3,4
 
Negative 
(1º: Purified rabbit polyclonal; 
Novocastra, Leica Biosystems.  
2 º: Leica Bond System) 
Not assessed 
SMA Not known Negative 
(1º: Clone ⍺sm-1, mouse 
monoclonal anti-human; 
Novocastra, Leica Biosystems.  
2 º: Leica Bond System) 
Negative 
(1º: Clone 1A4 mouse monoclonal 
anti-human; Dako, Agilent.  2 º: 
Dako Flex Kit) 
MUM-1 Not known Negative 
(1º: Clone MUM1p, mouse 
monoclonal anti-human; Dako, 
Agilent.  2 º: Dako Flex Kit) 
Not assessed 
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Desmin Negative
4
 Not assessed Negative 
(1º: Clone D33 mouse monoclonal 
anti-human; Dako, Agilent.  2 º: 
Dako Flex Kit) 
Neuron-specific enolase 
(NSE) 
59% 
tumours 
positive
3
 
Not assessed Negative 
(1º: Clone BBS/NC/VI-H14 
 mouse monoclonal anti-human; 
Dako, Agilent.  2 º: Dako Flex Kit) 
Glial fibrillary acidic 
protein (GFAP) 
Not known Not assessed Negative 
(1º: Polyclonal rabbit anti-; Dako, 
Agilent.  2 º: Dako Flex Kit) 
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